Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Waldenström's macroglobulinemia is a disease of mature B cells, the genetic basis of which is poorly understood. Few recurrent chromosomal abnormalities have been reported, and their prognostic value is not known. We conducted a prospective cytogenetic study of Waldenström's macroglobulinemia and examined the prognostic value of chromosomal aberrations in an international randomized trial. The main aberrations were 6q deletions (30%), trisomy 18 (15%), 13q deletions (13%), 17p (TP53) deletions (8%), trisomy 4 (8%), and 11q (ATM) deletions (7%). There was a significant association between trisomy of chromosome 4 and trisomy of chromosome 18. Translocations involving the IGH genes were rare (<5%). Deletion of 6q and 11q, and trisomy 4, were significantly associated with adverse clinical and biological parameters. Patients with TP53 deletion had short progression-free survival and short disease-free survival. Although rare (<5%), trisomy 12 was associated with short progression-free survival. In conclusion, the cytogenetic profile of Waldenström's macroglobulinemia appears to differ from that of other B-cell lymphomas. Chromosomal abnormalities may help with diagnosis and prognostication, in conjunction with other clinical and biological characteristics.
Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière and INSERM U872, UPMC Paris 6, France. florence.nguyen@psl.aphp.fr
Florence
F
Nguyen-Khac
Jerome
J
Lambert
Elise
E
Chapiro
Aurore
A
Grelier
Sarah
S
Mould
Carole
C
Barin
Agnes
A
Daudignon
Nathalie
N
Gachard
Stéphanie
S
Struski
Catherine
C
Henry
Dominique
D
Penther
Hossein
H
Mossafa
Joris
J
Andrieux
Virginie
V
Eclache
Chrystèle
C
Bilhou-Nabera
Isabelle
I
Luquet
Christine
C
Terre
Laurence
L
Baranger
Francine
F
Mugneret
Jean
J
Chiesa
Marie-Joelle
MJ
Mozziconacci
Evelyne
E
Callet-Bauchu
Lauren
L
Veronese
Hélène
H
Blons
Roger
R
Owen
Julie
J
Lejeune
Sylvie
S
Chevret
Hélène
H
Merle-Beral
Véronique
V
Leblondon
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D002882:Chromosomes, Human, Pair 13 / Q000235:genetics; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D002887:Chromosomes, Human, Pair 18 / Q000235:genetics; D002894:Chromosomes, Human, Pair 4 / Q000235:genetics; D002896:Chromosomes, Human, Pair 6 / Q000235:genetics; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D053208:Kaplan-Meier Estimate; D059785:Karyotype; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D014314:Trisomy; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology
D000970:Antineoplastic Agents; D002699:Chlorambucil; D014740:Vidarabine; C024352:fludarabine